GeneDx Holdings (WGS) stock plummeted 9.41% in the pre-market trading on Tuesday, despite the company reporting strong preliminary financial results for the fourth quarter and full year of 2024.
The genetic testing company said it expects to report revenues of at least $299 million for the full year 2024, up 54% year-over-year and above its previous guidance range of $284-$290 million. For the fourth quarter, GeneDx anticipates revenues of at least $92 million, representing a 59% increase from the same period last year and a 20% sequential growth.
Additionally, GeneDx achieved profitability, with the company expecting to report adjusted net income for the second consecutive quarter and positive operational cash flow for the first time. The strong financial performance was driven by the growing adoption of GeneDx's genetic testing services as the company continues to expand its product offerings and team.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。